Pomdoctor Ltd is an online medical services platform for chronic diseases in China... Show more
PomDoctor Limited positions itself as a digital healthcare company advancing AI-enabled (artificial intelligence) and predictive healthcare solutions for chronic disease management in China. Its four-tier revenue structure reflects a deliberate strategic evolution: B2C basic healthcare services serve as the established operating foundation, while AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services are designed to add recurring, higher-margin, and institutional revenue streams.
The company's competitive advantage centers on an integrated ecosystem that links its internet hospital platform, physician network, and pharmaceutical supply chain. Audited net revenue reached approximately RMB399.9 million (about US$59.04 million) in fiscal 2025, up from roughly RMB304.9 million in 2023 and RMB342.6 million in 2024, providing a foundation for the technology-enabled expansion it now emphasizes. The medium-term thesis hinges on whether PomDoctor can convert its established patient and physician relationships into durable subscription and data-services revenue, rather than relying solely on pharmaceutical transactions.
Structurally, the company remains a micro-cap with limited scale, negative equity, and a negative interest-coverage ratio, which heightens execution risk as it competes against larger, better-capitalized digital health and pharmacy platforms.
Several developments could shape investor sentiment over the coming quarters. First, the ramp of AI-enabled chronic disease membership subscriptions represents a pivotal test of the company's recurring-revenue thesis. Success in converting users into paying members with ongoing monitoring, risk alerts, and physician support would signal higher-margin, more predictable revenue.
Second, the commercialization of pharmaceutical RWS and RWD services is a potential long-term value driver. PomDoctor has already established commercial relationships with pharmaceutical partners, and any expansion of evidence-based research or data-service agreements would demonstrate a new revenue channel beyond direct patient transactions.
Third, integrated in-hospital and out-of-hospital chronic disease management pilots could validate the company's closed-loop AI framework. Progress here may attract institutional partnerships and strengthen its B2B narrative.
Finally, corporate and legal developments remain important. The company terminated its American Depositary Receipt (ADR) program in late 2026 and shifted to a direct listing of Class A ordinary shares, a structural change investors should monitor. Because analyst coverage is sparse, there is no widely cited consensus rating or price-target revision trend to gauge institutional sentiment, making company-issued progress updates and regulatory filings the primary catalysts to watch.
PomDoctor's trajectory is closely tied to structural trends in China's healthcare system. A rapidly aging population and the growing prevalence of chronic conditions such as hypertension and diabetes underpin long-term demand for continuous, technology-enabled care management. Policy support for internet hospitals and digital health also provides a favorable backdrop.
At the same time, the business is highly sensitive to China's regulatory climate, particularly around healthcare data privacy, AI applications in medicine, and pharmaceutical distribution. Macroeconomic factors, including consumer spending capacity and healthcare reimbursement policies, directly influence patient demand and pharmaceutical transaction volumes. Interest-rate and liquidity conditions also matter for a small-cap growth company that may require external capital, while the financing environment for emerging Chinese issuers listed on U.S. exchanges remains a structural consideration.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is designed to help users identify developing trends, evaluate potential breakouts or reversals, and explore predictions across a broad range of tradable instruments. It includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For those monitoring PomDoctor's evolving setup, the Trend Prediction Engine offers a data-driven complement to fundamental analysis.
Looking toward 2026 and beyond, PomDoctor's long-term story revolves around its transition from an episodic, transaction-based pharmacy business to a continuous, data-driven chronic care platform. The most consequential themes include whether membership subscriptions achieve meaningful scale, whether B2B and RWS/RWD services diversify revenue, and whether the company's AI models demonstrate measurable clinical and commercial value.
Margin sustainability will depend on shifting toward higher-margin subscription and data revenue while controlling the costs of wearable integration and remote monitoring. Capital allocation and balance-sheet repair are also central, given negative equity and weak interest coverage. Competitive threats from larger digital health platforms, regulatory changes affecting healthcare data and AI, and the ongoing securities litigation all represent factors that could alter the outlook.
Because consensus analyst coverage remains limited, long-term sentiment is likely to be shaped more by company execution, partnerships, and regulatory developments than by formal price targets. Investors should treat any external projections as factual analyst expectations rather than independent forecasts, and weigh the company's strategic ambition against its execution risks and small-cap volatility.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that POM and SCNX have been poorly correlated (+5% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POM and SCNX's prices will move in lockstep.
| Ticker / NAME | Correlation To POM | 1D Price Change % | ||
|---|---|---|---|---|
| POM | 100% | +10.56% | ||
| SCNX - POM | 5% Poorly correlated | +2.65% | ||
| RDGT - POM | -0% Poorly correlated | -4.25% | ||
| HITI - POM | -1% Poorly correlated | -1.12% | ||
| HKPD - POM | -3% Poorly correlated | +1.39% | ||
| PETS - POM | -9% Poorly correlated | -0.84% |
| Ticker / NAME | Correlation To POM | 1D Price Change % |
|---|---|---|
| POM | 100% | +10.56% |
| Drugstore Chains industry (5 stocks) | 16% Poorly correlated | -6.91% |
Industry DrugstoreChains
POM moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 3 of 3 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 8 of 10 cases where POM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on POM as a result. In 15 of 19 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for POM just turned positive on October 21, 2026. Looking at past instances where POM's MACD turned positive, the stock continued to rise in 4 of 7 cases over the following month. The odds of a continued upward trend are 57%.
The 10-day moving average for POM crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +43.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where POM advanced for three days, in 56 of 63 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The 10-day RSI Indicator for POM moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 4 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
POM broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: POM's P/B Ratio (0.000) is slightly lower than the industry average of (1.425). P/E Ratio (0.000) is within average values for comparable stocks, (-2.228). POM's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.947). Dividend Yield (0.000) settles around the average of (0.254) among similar stocks. P/S Ratio (0.043) is also within normal values, averaging (2.504).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. POM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.